CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 474-486

  Lindemann, Lothar ^a   Jaeschke, Georg ^b   Michalon, Aubin ^a   Vieira, Eric ^b   Honer, Michael ^a   Spooren, Will ^a   Porter, Richard ^b   Hartung, Thomas ^b   Kolczewski, Sabine ^b   Büttelmann, Bernd ^b   Flament, Christophe ^b   Diener, Catherine ^a   Fischer, Christophe ^a   Gatti, Silvia ^a   Prinssen, Eric P ^a   Parrott, Neil ^b   Hoffmann, Gerhard ^b   Wettstein, Joseph G ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 ((2,5 DIMETHYL 1 (4 [TRIFLUOROMETHOXY]PHENYL) 1H IMIDAZOL 4 YL)ETHYNYL)PRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; FENOBAM; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; CALCIUM; CYCLIC AMP; DRUG EVALUATION, PRECLINICAL; FEVER; HEK293 CELLS; HUMANS; IMIDAZOLES; INOSITOL PHOSPHATES; MALE; MICE; MOLECULAR TARGETED THERAPY; PLASMIDS; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 80054784232     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185660     Document Type: Article

References (43)

1. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, Hintermann S, Auberson Y, Gasparini F, Fischer UC, et al. (2007) Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med 48:247-252.
2. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, and Spooren W (2005) The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 179:218-229.
3. Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974.
4. Bockaert J, Perroy J, Bécamel C, Marin P, and Fagni L (2010) GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol 50:89-109.
5. Bosworth N and Towers P (1989) Scintillation proximity assay. Nature 341:167-168.
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, et al. (2003) 3-[(2-Methyl-1,3- thiazol-4- yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
8. Faherty CJ, Raviie Shepherd K, Herasimtschuk A, and Smeyne RJ (2005) Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 134:170-179.
9. Friedmann CTH, Davis LJ, Ciccone PE, and Rubin RT (1980) Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr Ther Res 27:144-151.
10. Gasparini F, Bilbe G, Gomez-Mancilla B, and Spooren W (2008) mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Dev 11:655-665.
11. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl)- pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
12. Hamilton NB and Attwell D (2010) Do astrocytes really exocytose neurotransmitters? Nat Rev Neurosci 11:227-238.
13. Heidbreder CA, Bianchi M, Lacroix LP, Faedo S, Perdona E, Remelli R, Cavanni P, and Crespi F (2003) Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50:269-276.
14. Hintermann S, Vranesic I, Allgeier H, Brülisauer A, Hoyer D, Lemaire M, Moenius T, Urwyler S, Whitebread S, Gasparini F, et al. (2007) ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg Med Chem 15:903-914.
15. Ickes BR, Pham TM, Sanders LA, Albeck DS, Mohammed AH, and Granholm AC (2000) Long-term environmental enrichment leads to regional increases in neurotrophin levels in rat brain. Exp Neurol 164:45-52.
16. Itil TM, Seaman BA, Huque M, Mukhopadhyay S, Blasucci D, Nq KT, and Ciccone PE (1978) The clinical and quantitative EEG effects and plasma levels of fenbam (McN-3377) in subjects with anxiety: An open rising dose tolerance and efficacy study. Curr Ther Res 24:708-724.
17. Jaeschke G, Wettstein JG, Nordquist RE, and Spooren W (2008) mGlu5 receptor antagonists and their therapeutic potential. Exp Opin Ther Patents 18:123-142.
18. Jong YJ, Kumar V, and O'Malley KL (2009) Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J Biol Chem 284:35827-35838.
19. Kansy M, Senner F, and Gubernator K (1998) Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
20. Kew JN and Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179:4-29.
21. Kuhlmann O, Paehler A, Weick I, Funk C, Pantze M, Zell M, and Timm U (2010) Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica 40:840-852.
22. Kuhn R, Pagano A, Stoehr N, Vranesic I, Flor PJ, Lingenhöhl K, Spooren W, Gentsch C, Vassout A, Pilc A, et al. (2002) In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. Amino Acids 23:207-211.
23. Lapin IP (1995) Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze. J Pharmacol Toxicol Methods 34:73-77.
24. Lea PM 4th and Faden AI (2006) Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 12:149-166.
25. Liu X, Vilenski O, Kwan J, Apparsundaram S, and Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37:1548-1556.
26. Malherbe P, Kratochwil N, Mühlemann A, Zenner MT, Fischer C, Stahl M, Gerber PR, Jaeschke G, and Porter RH (2006) Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J Neurochem 98:601-615.
27. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, Fischer C, and Porter RH (2003) Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6- (phenylethynyl)-pyridine. Mol Pharmacol 64:823-832.
28. Martínez-Cué C, Baamonde C, Lumbreras M, Paz J, Davisson MT, Schmidt C, Dierssen M, and Flórez J (2002) Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav Brain Res 134:185-200.
29. Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C, and Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030.
30. Nithianantharajah J and Hannan AJ (2006) Enriched environments, experiencedependent plasticity and disorders of the nervous system. Nat Rev Neurosci 7:697-709.
31. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezèau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen- 1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
32. Paxinos G and Franklin KBJ (2003) The Mouse Brain in Stereotaxic Coordinates, 2nd Ed, Academic Press, New York.
33. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, and Allan T (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 2:129-133.
34. Porter RH, Jaeschke G, Spooren W, Ballard TM, Büttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, et al. (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315:711-721.
35. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, and Ammassari- Teule M (2005) Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A 102:11557-11562.
36. Ribeiro FM, Paquet M, Cregan SP, and Ferguson SS (2010) Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets 9:574-595.
37. Simonyi A, Schachtman TR, and Christoffersen GR (2005) The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18:353-361.
38. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, and Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277.
39. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, and Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-170.
40. Tatsumi M, Groshan K, Blakely RD, and Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258.
41. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, et al. (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181.
42. Wan H and Holmén AG (2009) High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen 12:315-329.
43. Wu WN, McKown LA, and O'Neill PJN (1995) In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J Pharm Sci 84:185-189.